Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice[J]. Nature, 1994, 367(6464): 645-648.
[2]
Al-Hajj M, Wicha MS, Benito-Hernandez A, et al. Prospective identification of tumorigenic breast cancer cells[J]. Proc Natl Acad Sci USA, 2003, 100(7): 3983-3988.
[3]
Singh SK, Hawkins C, Clarke ID, et al. Identification of human brain tumour initiating cells[J]. Nature, 2004, 432(7015): 396-401.
[4]
Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea-a paradigm shift[J]. Cancer Res, 2006, 66(4): 1883-1890.
[5]
Dalerba P, Cho RW, Clarke MF. Cancer stem cells: models and concepts[J]. Annu Rev Med, 2007, 58: 267-284.
[6]
Bertolini G, Roz L, Perego P, et al. Highly tumorigenic lung cancer CD133？+ cells display stem-like features and are spared by cisplatin treatment[J]. Cell Bio, 2009, 106(38): 16281-16286.
Carney DN, Gazdar AF, Bunn PJ, et al. Demonstration of the stem cell nature of clonogenic tumor cells from lung cancer patients[J]. Stem Cells, 1982, 1(3): 149-164.
[9]
Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cells in normal lung and lung cancer[J]. Cell, 2005, 121(6): 823-835.
[10]
Mori M, Rao SK, Popper HH, et al. Atypical adenomatous hyperplasia of the Lung: a probable forerunner in the development of adenocarcinoma of the lung[J]. Mod Pathol, 2001, 14(2): 72-84.
[11]
Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population[J]. Cell Death Differ, 2008, 15(3): 504-514.
[12]
Levina V, Marrangoni AM, DeMarco R, et al. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties[J]. PLoS One, 2008, 3(8): 3077.
[13]
Tirino V, Camerlingo R, Franco R, et al. The role of CD133 in the identification and characterisation of tumor-initiating cells in non-small-cell lung cancer[J]. Eur J Cardiothorac Surg, 2009, 36(3): 446-453.
[14]
Meng XJ, Li M, Wang XW, et al. Both CD133？+ and CD133？- subpopulations of A549 and H446 cells contain cancer-initiating cells[J]. Cancer Sci, 2009, 100(6): 1040-1046.
[15]
Goodell MA, Brose K, Paradis G, et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo[J]. J Exp Med, 1996, 183 (4): 1797-1806.
[16]
Zhou S, Schuetz JD, Bunting KD, et al. The ABC transporter Brcp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side population phenotype[J]. Nat Med, 2001, 7(9): 1028-1034.
[17]
Ho MM, Ng AV, Lam S, et al. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells[J]. Cancer Res, 2007, 67(10): 4827-4833.
[18]
Sung JM, Cho HJ, Yi H, et al. Characterization of a stem cell population in lung cancer A549 cells[J]. Biochem Biophys Res Commun, 2008, 371(1): 163-167.
[19]
Chen YC, Hsu HS, Chen YW, et al. Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells[J]. PLoS One, 2008, 3(7): 2637.
[20]
Yoshida A, Rzhetsky A, Hsu LC, et al. Human aldehyde dehydrogenase gene family[J]. Eur J Biochem, 1998, 251(3): 549-557.
[21]
Pearce DJ, Taussig D, Simpson C, et al. Characterization of cells with a high aldehyde dehydrogenase activity from cord blood and acute myeloid leukemia samples[J]. Stem Cells, 2005, 23(6): 752-760.
[22]
Ginestier C, Hur MH, Jauffert EC, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome[J]. Cell Stem Cell, 2007, 1(5): 555-567.
[23]
Ucar D, Cogle CR, Zucali JR, et al. Aldehyde dehydrogenase activity as a functional marker for lung cancer[J]. Chem Bio Interact, 2009, 178(1-3): 48-55.
[24]
Jiang F, Qiu Q, Khanna A, et al. Aldehyde Dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer[J]. Mol Cancer Res, 2009, 7(3): 330-338.
[25]
Zhou R, Liu Q, Todd NW, et al. Evaluation of aldehyde dehydrogenase 1 (ALDH1) as a marker of non-small cell lung cancer (NSCLC) stem cells (SCs) and correlation with prognosis[J]. J Clin Oncol, 2009, 27(Suppl 15): 11105.
[26]
Mani SA, Guo WJ, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells[J]. Cell, 2008, 133(4): 704-715.
[27]
Keshamouni VG, Michailidis G, Grasso CS, et al. Differential protein expression profiling by iTRAQ-2DLC-MS/MS of lung cancer cells undergoing epithelial-mesenchymal transition reveals a mgratory/invasive phenotype[J]. J Proteome Res, 2006, 5(5): 1143-1154.
[28]
Nozawa N, Hashimoto S, Nakashima Y, et al. Immunohistochemical alpha-and beta-caterfin and E-cadherin expression and their clinicopathologicaI significance in human lung adenocarcinoma[J]. Patho Res Pract, 2006, 202(9): 639-650.
[29]
Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition[J]. Cancer Res, 2005, 65(20): 9455-9462.
[30]
Gupta PB, Onder TT, Jiang GZ, et al, Identification of selective inhibitors of cancer stem cells by high-throughput screening[J]. Cell, 2009, 138(4): 645-659.
